NCT04826185View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

June 14, 2021

Primary Completion Date

September 18, 2023

Study Completion Date

September 18, 2023

Conditions
Non-obstructive Hypertrophic Cardiomyopathy
Interventions
DRUG

IMB-1018972

Modified release (MR) oral tablet

DRUG

Placebo

Matching oral tablet

Trial Locations (14)

10016

Imbria Investigational Site, New York

28203

Imbria Investigational Site, Charlotte

60611

Imbria Investigational Site, Chicago

63110

Imbria Investigational Site, St Louis

77030

Imbria Investigational Site, Houston

84112

Imbria Investigational Site, Salt Lake City

90048

Imbria Investigational Site, Los Angeles

92093

Imbria Investigational Site, La Jolla

94143

Imbria Investigational Site, San Francisco

97239

Imbria Investigational Site, Portland

02111

Imbria Investigational Site, Boston

01805

Imbria Investigational Site, Burlington

07960

Imbria Investigational Site, Morristown

Unknown

Imbria Investigational Site, Oxford

Sponsors
All Listed Sponsors
lead

Imbria Pharmaceuticals, Inc.

INDUSTRY